Shanghai Pioneer Holding Ltd (SH PIONEER HLDG, 01345) reported that a wholly owned subsidiary has entered into an exclusive, long-term distribution agreement with Labo International S.r.l., the Italian affiliate of Switzerland’s Labo Cosprophar AG. Under the accord, Shanghai Pioneer Holding gains sole rights to sell and promote the “LABO HAIR LOSS萊珀海洛詩” anti-hair-loss vials throughout the People’s Republic of China.

The topical cosmetic treatment, formulated with several proprietary active complexes, targets physiological and non-pathological hair loss. It secured special-cosmetic marketing approval from China’s National Medical Products Administration in December 2025 after completing efficacy and safety trials.

Management highlighted the agreement’s strategic value, pointing to rising hair-loss prevalence and strengthening consumer demand for proven hair-care solutions in China. The group’s Beauty Division will roll out tailored marketing initiatives and expand distribution channels to accelerate product uptake.

The voluntary announcement, dated 30 March 2026 and signed by Chairman Li Xinzhou, signals Shanghai Pioneer Holding’s commitment to enlarging its presence in the domestic beauty and personal-care market while seeking enhanced returns for shareholders.